EUCTR2011-002276-16-ES进行中（未招募）1 期
A randomised, double-blind, double-dummy active-comparator controlled study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at bedtime versus metformin BID over 14 weeks in treatment naive type 2 diabetes and insufficient glycaemic control.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Diagnosis of Type 2 diabetes mellitus prior to informed consent;
- •2. Male and female patients on diet and excise regimen who are drug naive, defined as abesense of any oral antidiabetic therapy or insulin for 12 weeks prior to randomization
- •3. Glycoslylated haemoglobin A1c (HbA1c) >/= 6.5% (48 mmol/mol) to 4. Age>/=18 and 5. Body Mass Index(BMI)6. Signed and dated written informed consent by date of visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •1.Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (13.3mmol/L) after an overnight fast during screening/placebo run-in and confirmed by a second measurement (Not on the same day);
- •2.Treatment with any oral antidiabetic drug or insulin within 12 weeks prior to randomization
- •3. Myocaridial infarction,stroke or Transient ischemia attack (TIA) within 3 months prior to informed consent;
- •4. Indication of liver disease/Impaired hepatic function, defined by serum levels of either Aspartate aminotransferase (ALT or SGPT), alanine aminotransferase (AST or SGOT), or alkaline phosphatase above 3 x uppler limit of normal (ULN) as determined at visit 1,
- •5. Impaired renal function fuction, defined as eGFR< 60ml/min (severe renal impairement, modification of diet in renal disease (MDRD) formula) as determined at run-in phase
- •6. Bariatric surgery within the past two years and other gastrointestinal surgeries that induced chronic malaborption
- •7. Medical history of Cancer(except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
- •8. Blood dyscrasia or any other disorders causing hemolysis or unstable Red Blood Cell (eg. malaria, babesiosis, hamolytic anemia)
- •9. Contraindications to moetformin according to the local label
- •10. Treatment with anti-obesity drugs 3 months prior to informed consent or any otehr treatment at the time of screening (i.e. surgery, aggressive diet regimen etc) leading to unstable body weight
- •12. Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who:
- •a. are nursing or pregnant or
- •b. are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to contiune using this method throughout the study and do not agree to submit to periodic pregancy testing during parcipation in the trial. Acceptable methods of birth control include transdermal patch, intra-uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.
- •13. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
- •14. Participation in another trial with application of any investigational drug within 30 days prior to informed consent
- •15. Any other clinical condition that would jeopardize patients safety while participating in this trial
研究者
相似试验
进行中（未招募）
不适用
linagliptin in combination with metformin in treatment naive patients with type 2 diabetes mellitus and insufficient glycaemic controlType 2 diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002276-16-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,360
进行中（未招募）
1 期
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus VulgarisPemphigus Vulgaris (PV)MedDRA version: 17.1Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2014-000382-41-ITF. Hoffmann-La Roche Ltd135
进行中（未招募）
1 期
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus VulgarisPemphigus Vulgaris (PV)MedDRA version: 17.1 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858EUCTR2014-000382-41-ESF. Hoffmann-La Roche Ltd135
进行中（未招募）
1 期
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus VulgarisEUCTR2014-000382-41-DEF. Hoffmann-La Roche Ltd132
进行中（未招募）
1 期
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus VulgarisPemphigus Vulgaris (PV)MedDRA version: 18.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858EUCTR2014-000382-41-FRF. Hoffmann-La Roche Ltd135